Myelodysplastic Syndrome News
Vidaza® Improves Survival in Higher-risk Myelodysplastic Syndromes (March 6, 2009)According to the results of a Phase III clinical trial, treatment with Vidaza® (azacitidine) results in better survival than conventional care among patients with higher-risk myelodysplastic syndromes (MDS). These results were published in Lancet Oncology. Myelodysplastic... Continue Reading
The American Society of Clinical Oncology 2008: Highlights of Treatment of Hematological Malignancies (January 30, 2009)The American Society of Clinical Oncology 2008: Highlights of Treatment of Hematological Malignancies The 2008 annual meeting of the American Society of Clinical Oncology (ASCO), held in Chicago, Illinois, again revealed advances in the treatment of... Continue Reading
New Risk Model for MDS Applies to All Stages of Disease (December 31, 2008)New Risk Model for MDS Applies to All Stages of Disease A new risk model for myelodysplastic syndrome (MDS) provides survival projections for all stages of the disease and has proven superior to the International Prognostic Scoring System (IPSS) that... Continue Reading
Older Age Does Not Affect Survival in Patients with AML or MDS Who Undergo Mini-transplants (December 30, 2008)Older Age Does Not Affect Survival in Patients with AML or MDS Who Undergo Mini-transplants Age should not be a barrier for non-myeloablative allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome... Continue Reading
Vidaza® Approved for High-risk MDS (August 22, 2008)Vidaza® Approved for High-risk MDS The US Food and Drug Administration (FDA) has approved Vidaza® (azacitadine) for the treatment of high-risk myelodysplastic syndromes. Vidaza is already approved for MDS that is categorized into all five French American... Continue Reading
Supportive Care and Hematologic Malignancies (January 21, 2008)Supportive Care and Hematologic Malignancies: A Report from the 2007 American Society of Hematology (ASH) Meeting Introduction At the 2007 meeting of the American Society of Hematology (ASH) the most interesting supportive care studies involved second... Continue Reading
Updates in the Management of Myelodysplastic Syndromes (January 21, 2008)Updates in the Management of Myelodysplastic Syndromes: A Report from the 2007 American Society of Hematology (ASH) Meeting IntroductionCytopenias – The Double-Edged SwordHypomethylating Agents – Living the Good LifeImmunomodulatory Agents Extend... Continue Reading
Latest Myelodysplastic Syndrome News By Stage
General Myelodysplastic Syndrome
Vidaza® Improves Survival in Higher-risk Myelodysplastic Syndromes (March 6, 2009)
According to the results of a Phase III clinical trial, treatment with Vidaza® (azacitidine) results in better survival than conventional care among patients with higher-risk myelodysplastic syndromes (MDS). These results were published in Lancet Oncology. Myelodysplastic... Continue Reading
The American Society of Clinical Oncology 2008: Highlights of Treatment of Hematological Malignancies (January 30, 2009)The American Society of Clinical Oncology 2008: Highlights of Treatment of Hematological Malignancies The 2008 annual meeting of the American Society of Clinical Oncology (ASCO), held in Chicago, Illinois, again revealed advances in the treatment of... Continue Reading
New Risk Model for MDS Applies to All Stages of Disease (December 31, 2008)New Risk Model for MDS Applies to All Stages of Disease A new risk model for myelodysplastic syndrome (MDS) provides survival projections for all stages of the disease and has proven superior to the International Prognostic Scoring System (IPSS) that... Continue Reading
Older Age Does Not Affect Survival in Patients with AML or MDS Who Undergo Mini-transplants (December 30, 2008)Older Age Does Not Affect Survival in Patients with AML or MDS Who Undergo Mini-transplants Age should not be a barrier for non-myeloablative allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome... Continue Reading
Vidaza® Approved for High-risk MDS (August 22, 2008)Vidaza® Approved for High-risk MDS The US Food and Drug Administration (FDA) has approved Vidaza® (azacitadine) for the treatment of high-risk myelodysplastic syndromes. Vidaza is already approved for MDS that is categorized into all five French American... Continue Reading
More General Myelodysplastic Syndrome